The identified prognostic genes, particularly GRAMD1A, SPR, EBAG9, RBM47, and RIDA, offer significant potential as both prognostic biomarkers and therapeutic targets for improving personalized treatment in Wilms tumor patients. This evidence concerns the gene GRAMD1A and Wilms tumor.